BiosYnth SRL
Research laboratories focused on discovery and development of bacterial and viral vaccines. Core activities include design and synthesis of glycoconjugate vaccines, development of nanostructured antigen delivery systems, discovery and production of synthetic anti-endotoxin peptides, GLP-compliant preclinical research, pilot-scale process development and patenting/licensing of platform technologies. Operations are based in Rapolano Terme (Siena), Italy, with over 40 years of activity and a patent portfolio supporting vaccine and peptide platforms.
Industries
N/A
Products
Multivalent glycoconjugate vaccine candidates (pneumococcal)
Conjugate vaccine prototypes capable of including multiple capsular antigens (up to 20 serotypes) formulated using high-yield conjugation chemistries for pediatric and adult immunization.
Meningococcal conjugate and endotoxoid-based vaccine candidates
Prototype vaccines for meningococcal groups (ACWY and Group B) including endotoxoid (detoxified LPS) concepts evaluated for safety in early clinical testing.
Prototype vaccines for antibiotic-resistant bacterial pathogens
Vaccine prototypes targeting multidrug-resistant bacteria including Clostridium difficile, Escherichia coli, Salmonella typhi/Paratyphi, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii.
Nanostructured vector-based viral subunit vaccine candidates
Subunit vaccine prototypes for respiratory and systemic viruses (SARS-CoV-2, RSV, Influenza, Dengue 2, HIV) employing nanostructured antigen presentation to enhance T-helper responses.
Multivalent glycoconjugate vaccine candidates (pneumococcal)
Conjugate vaccine prototypes capable of including multiple capsular antigens (up to 20 serotypes) formulated using high-yield conjugation chemistries for pediatric and adult immunization.
Meningococcal conjugate and endotoxoid-based vaccine candidates
Prototype vaccines for meningococcal groups (ACWY and Group B) including endotoxoid (detoxified LPS) concepts evaluated for safety in early clinical testing.
Prototype vaccines for antibiotic-resistant bacterial pathogens
Vaccine prototypes targeting multidrug-resistant bacteria including Clostridium difficile, Escherichia coli, Salmonella typhi/Paratyphi, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii.
Nanostructured vector-based viral subunit vaccine candidates
Subunit vaccine prototypes for respiratory and systemic viruses (SARS-CoV-2, RSV, Influenza, Dengue 2, HIV) employing nanostructured antigen presentation to enhance T-helper responses.
Services
Vaccine R&D services
Research and development services from antigen identification and formulation optimization through preclinical evaluation in GLP-compliant facilities.
Pilot-scale process development and peptide manufacturing
Optimization and small-scale production of vaccine conjugates and synthetic peptides intended for preclinical and early clinical use.
IP portfolio management and licensing
Patent development, management and licensing support for conjugate, peptide and nanostructured vector technologies.
Vaccine R&D services
Research and development services from antigen identification and formulation optimization through preclinical evaluation in GLP-compliant facilities.
Pilot-scale process development and peptide manufacturing
Optimization and small-scale production of vaccine conjugates and synthetic peptides intended for preclinical and early clinical use.
IP portfolio management and licensing
Patent development, management and licensing support for conjugate, peptide and nanostructured vector technologies.
Expertise Areas
- Vaccine research and development
- Glycoconjugate vaccine technology
- Nanostructured antigen delivery
- Antimicrobial and anti-endotoxin peptides
Key Technologies
- Glycoconjugation chemistry
- Nanostructured antigen vectors / nanoparticle-like vectors
- Synthetic peptide design and production
- Endotoxin (LPS) detoxification complexes